LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VRDN
Viridian Therapeutics, Inc.
There isn't enough reported data to score VRDN yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VRDN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
VRDN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VRDN PE Valuation
VRDN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VRDN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect VRDN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus VRDN down 190%.
VRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.86 | +$0.44 |
| Q2 2025 | -$4.65 | -$0.41 |
| Q1 2025 | -$4.44 | +$0.05 |
| Q4 2024 | -$4.16 | +$1.15 |
| Q3 2024 | -$4.30 | +$0.82 |
| Q2 2024 | -$4.24 | +$0.65 |
| Q1 2024 | -$4.49 | +$0.19 |
| Q4 2023 | -$5.31 | -$1.26 |
VRDN is still losing money, but far less than before: $3.86 per share over the past year, against $31.75 at its worst in mid-2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VRDN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VRDN on profitability, with a higher operating margin.
VRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.8M | -64% |
| Q2 2026 | $284K | +279% |
| Q1 2026 | $141K | +96% |
| Q4 2025 | $132K | +83% |
| Q3 2025 | $70.6M | +81958% |
| Q2 2025 | $75K | +4.2% |
| Q1 2025 | $72K | 0% |
| Q4 2024 | $72K | 0% |
VRDN's revenue has slid since its 2025 peak: $26M last quarter, down 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -402% | -345 points |
| Q2 2026 | -44461% | +97895 points |
| Q1 2026 | -82389% | +47980 points |
| Q4 2025 | -92992% | +28497 points |
| Q3 2025 | -57% | +97013 points |
| Q2 2025 | -142356% | -42096 points |
| Q1 2025 | -130369% | -52735 points |
| Q4 2024 | -121489% | -22214 points |
VRDN's operating margin was −402% last quarter, down 345 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VRDN on cash generation, producing positive trailing cash flow while its opponent burns cash.
VRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$93.1M | -$8.4M |
| Q2 2026 | -$106.6M | -$31.2M |
| Q1 2026 | -$119.7M | -$26.9M |
| Q4 2025 | -$24M | +$49.5M |
| Q3 2025 | -$84.7M | -$16.7M |
| Q2 2025 | -$75.4M | -$29.3M |
| Q1 2025 | -$92.7M | -$47.5M |
| Q4 2024 | -$73.4M | -$35.4M |
VRDN has burned cash in almost every quarter: −$343M over the past year, against −$326M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VRDN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +266K shares |
| 1 year | +19% | +18.1M shares |
| 3 years | +163% | +70.3M shares |
| 5 years | +2953% | +110M shares |
VRDN has 114M diluted shares, up 19% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VRDN Net Leverage
VRDN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.2 | Neutral |
| Stochastic | 91.0 | Overbought |
VRDN's weekly RSI is 69 (neutral) and its Stochastic is 91 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VRDN PE vs Healthcare Sector
VRDN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
VRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.0 | 33% above |
| 20 week MA | $21.9 | 39% above |
| 50 week MA | $23.3 | 31% above |
| 100 week MA | $20.7 | 48% above |
| 200 week MA | $20.4 | 49% above |
VRDN is in an uptrend: it's above all five of its weekly moving averages, and 49% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VRDN on returns for 2026, with the stronger performance.
VRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.62 | $17.6 | +131% |
| 2021 | $17.6 | $21.5 | +22% |
| 2022 | $21.5 | $29.6 | +38% |
| 2023 | $29.6 | $21.8 | -26% |
| 2024 | $21.8 | $19.5 | -11% |
| 2025 | $19.5 | $31.9 | +64% |
| 2026 YTD | $31.9 | $30.5 | -4.4% |
VRDN has finished higher in four of the last six years, two of them by more than 50%. It's down 4.4% so far in 2026.